Dr Sachin Wani, from the University of Colorado Anschutz Medical Campus, reports on key findings from studies affecting patients with esophageal disease, presented at Digestive Disease Week 2022.
First, Dr Wani discusses a trial that reviewed electronic health records to determine real-world clinical outcomes of patients with Barrett esophagus who underwent endoscopic eradication therapy. He then examines a trial that provided potentially practice-changing results in comparing vonoprazan vs the proton pump inhibitor lansoprazole for treating erosive esophagitis.
Next, Dr Wani looks at a 96-week extension study following the EOS-2 trial which showed that continued use of budesonide orodispersible tablets for patients with eosinophilic esophagitis continues to be highly effective at preventing clinical and endoscopic relapse.
Finally, Dr Wani discusses the predictive value of TissueCypher, a fully automated risk assessment for Barrett esophagus. The study compared the automated results with those of pathologists in determining the risk for malignant progression to high-grade dysplasia and esophageal adenocarcinoma in patients diagnosed with community-based low-grade dysplasia. The results indicate a future approach that may improve risk stratification.
Medscape © 2022 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Esophageal Diseases Highlights From DDW 2022 - Medscape - Jun 20, 2022.
Comments